title: Zuclopenthixol, D(1)/D(2) antagonist, for treatment of chronic aggressive schizophrenia and psychotic oligophrenic patients.
abstract: An open label trial was conducted to study the efficacy of zuclopenthixol decanoate, a D(1)/D(2) antagonist, in the treatment of chronic (> 10 years) neuroleptic-resistant aggressive schizophrenia (n = 10) and psychotic oligophrenic patients (n = 6). A significant reduction was noted in the Brief Psychiatric Rating Scale score, especially in the clusters of hostility-suspiciousness and excitement. After many years of seclusion, ten of the 16 patients were transferred to an open psychiatric department and were allowed to visit their families.
authors.affiliation: Mental Health Service, Israel Ministry of Health and Israel Defence Forces, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Grinshpoon
authors.forename: M
authors.initials: M
authors.lastname: Moskowitz
authors.forename: A
authors.initials: A
authors.lastname: Valevski
authors.forename: A
authors.initials: A
authors.lastname: Kreizman
authors.forename: L
authors.initials: L
authors.lastname: Palei
authors.forename: M
authors.initials: M
authors.lastname: Mar
authors.forename: A
authors.initials: A
authors.lastname: Weizman